


PHARMACEUTICAL 2023



DICE Therapeutics Inc. Rank 13 of 446





PHARMACEUTICAL 2023



DICE Therapeutics Inc. Rank 13 of 446



The relative strengths and weaknesses of DICE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DICE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of DICE Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 244% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	577,762
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,149
Liabilities, Non-Current	11,841
Other Assets	13,295
Other Compr. Net Income	-539
Other Expenses	679
Other Liabilities	0
Other Net Income	5,013
Other Revenues	0
Property and Equipment	2,921
Research and Development	62,559
Selling, General and Administrative Expense	25,662

Output Variable	Value in 1000 USD
Assets	593,978
Liabilities	26,990
Expenses	88,900
Revenues	0
Stockholders Equity	566,988
Net Income	-83,887
Comprehensive Net Income	-84,156
Economic Capital Ratio	287%

